A new analytical document titled "Intellectual Property and Access to Treatment in the Kyrgyz Republic (2025–2026)" highlights the need to refine national legislation. The study, prepared by the Partner Network association in collaboration with ITPC EECA, examines how patent protections impact the availability of medicines, vaccines, and medical technologies.
Key recommendations for legal reform
To ensure citizens can access vital treatments, experts suggest several mechanisms. These include developing compulsory licensing processes, improving patent procedures, and removing legal barriers that prevent generics and biosimilars from entering the market.
Aibar Sultangaziev, the Executive Director of the Partner Network health programs association, noted that as a member of the World Trade Organization (WTO), Kyrgyzstan has committed to protecting intellectual property. However, the current system requires adjustments to maintain a balance between these international obligations and public health needs.
Scope of the research
The analysis covers several critical legal areas that influence the pharmaceutical market in the country, including:
- Patentability criteria for inventions
- Patent challenge procedures
- Compulsory licensing mechanisms
- Parallel imports
- Registration of medicinal products







